Paul Bisaro - 15 Jul 2026 Form 4 Insider Report for Keenova Therapeutics plc

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 15 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jul 2026, 21:54:51 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Tyndall, Attorney-in-Fact

Key filing fact

Paul Bisaro filed Form 4 for Keenova Therapeutics plc on 17 Jul 2026.

Key facts

This page summarizes Paul Bisaro's Form 4 filing for Keenova Therapeutics plc.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jul 2026, 21:54.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001237253 Primary reporting owner

Bisaro Paul

Relationship: Director
Address: 440 ROUTE 22 EAST, SUITE 302, BRIDGEWATER
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Signature date: 17 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +4,406
Change %: +10%
Price: $0.000000^*
Shares after: 46,749
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 4,406
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.

Footnote F2

The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

SEC remarks

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.